Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRx-001 in advanced cholangiocarcinoma
NCT02452970Phase 2Terminated
- Sponsor
- EpicentRx
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Nibrozetone in cholangiocarcinoma (CCA), sponsored by EpicentRx. Primary endpoints: Progression-Free Survival and Overall Objective Response. Started Jul 2015; status: terminated.
02
Drugs
Nibrozetone
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02452970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452970.